Famotidine NDC 70756-052

NDC codes

FDA NDC Directory

Product NDC (as listed)70756-052Labeler and product segments. Claims need a package NDC.

Product NDC at billing width70756-0052Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
70756-052-11	70756005211	100 TABLET in 1 BOTTLE (70756-052-11)Marketed from Oct 19, 2023
70756-052-12	70756005212	1000 TABLET in 1 BOTTLE (70756-052-12)Marketed from Oct 19, 2023

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Famotidine
Generic name (nonproprietary): famotidine
Active ingredients: Famotidine — 40 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Lifestar Pharma LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 075302
Marketing start: Oct 19, 2023
Listing expires: Dec 31, 2026
Other FDA classes: Histamine H2 Receptor Antagonists (Mechanism)
Identifiers: Product ID 70756-052_8c901736-6453-4cbd-824d-073bc083e6aaSPL ID 8c901736-6453-4cbd-824d-073bc083e6aaSPL set ID 044a510f-33df-4484-8f07-d821f52b9376RxCUI 284245, 310273UNII 5QZO15J2Z8UPC 0370756051114, 0370756052111
Pharmacologic class: Histamine-2 Receptor Antagonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N470756005211 followed by a unit qualifier and the quantity

Package 70756-0052-11. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 22, 2024.

Indications (excerpt from the label)

Famotidinetablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: active duodenal ulcer (DU). active gastric ulcer (GU). symptomatic nonerosive gastroesophageal reflux disease (GERD). erosive esophagitis due to GERD, diagnosed by biopsy. Famotidinetablets are indicated in adults for the: treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). reduction of the risk of duodenal ulcer recurrence. Famotidine tablets are histamine-2 (H 2 ) receptor antagonist indicated (1): In adult and pediatric patients 40 kg and greater for the treatment of: active duodenal ulcer (DU). active gastric ulcer. sym…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 075302

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 075302
Product	Strength	Form · route	Labeler	Product NDC
Famotidine	Famotidine 20 mg/1	TabletOral	Redpharm Drug	67296-2133
Famotidine	Famotidine 20 mg/1	TabletOral	Lifestar Pharma LLC	70756-051